As expected, QoL expressed as utilities in younger patients was better (demonstrated by a higher value), which corresponds to many reports on QoL, both for the population and the patients.27, 28 It is noteworthy that the QoL gain was not affected by age and that older patients benefit equally from GH treatment compared to the younger patients in terms of utilities, supporting previous observations on the QoL response to GH in older patients with hypopituitarism.29 The gene discussed is GH1; the disease is hypopituitarism.